Time point | PDSS-2 score | p-value | p-value# | Post hoc tests# | ESS score | p-value | p-value# | Post hoc tests# | RBDSQ score | p-value | p-value# | Post hoc tests# |
MSA | ||||||||||||
Baseline | 9.60 ± 6.08 | < 0.001* | 0.033* | - | 4.81 ± 4.66 | < 0.001* | < 0.001* | a,b,c | 5.04 ± 3.40 | 0.010* | 0.009* | c |
1-year FU | 10.97 ± 7.05 | 6.41 ± 5.96 | 5.04 ± 3.01 | |||||||||
2-year FU | 12.36 ± 8.51 | 8.00 ± 6.93 | 5.97 ± 2.94 | |||||||||
MSA-P | α | |||||||||||
Baseline | 11.13 ± 6.52 | 0.014* | 0.234 | - | 6.13 ± 5.06 | < 0.001* | 0.001* | a,b,c | 4.92 ± 3.11 | 0.004* | 0.010* | c |
1-year FU | 12.64 ± 7.49 | 8.16 ± 6.31 | 4.99 ± 2.88 | |||||||||
2-year FU | 14.35 ± 9.53 | 9.70 ± 7.42 | 6.11 ± 2.93 | |||||||||
MSA-C | ||||||||||||
Baseline | 8.14 ± 5.27 | 0.001* | 0.026* | b | 3.57 ± 3.87 | < 0.001* | 0.003* | b | 5.15 ± 3.66 | 0.617 | 0.409 | - |
1-year FU | 9.39 ± 6.23 | 4.76 ± 5.10 | 5.09 ± 3.15 | |||||||||
2-year FU | 10.27 ± 6.80 | 6.23 ± 5.96 | 5.82 ± 2.98 | |||||||||
Male MSA | ||||||||||||
Baseline | 8.81 ± 5.63 | 0.057 | 0.480 | - | 5.10 ± 4.78 | < 0.001* | < 0.001* | a,b,c | 4.96 ± 3.40 | 0.070 | 0.098 | - |
1-year FU | 9.82 ± 6.48 | 6.95 ± 6.43 | 4.94 ± 3.11 | |||||||||
2-year FU | 10.48 ± 7.83 | 10.00 ± 7.29 | 6.02 ± 3.08 | |||||||||
Female MSA | ||||||||||||
Baseline | 10.44 ± 6.46 | < 0.001* | 0.021* | b | 4.51 ± 4.53 | < 0.001* | 0.061 | - | 5.11 ± 3.40 | 0.144 | 0.089 | - |
1-year FU | 12.22 ± 7.45 | 5.84 ± 5.38 | 5.15 ± 2.92 | |||||||||
2-year FU | 14.15 ± 8.83 | 6.09 ± 6.06 | 5.91 ± 2.84 | |||||||||
Time point | Presence of PD-SP | p-value | p-value# | Post hoc tests# | Presence of EDS | p-value | p-value# | Post hoc tests# | Presence of RBD | p-value | p-value# | Post hoc tests# |
MSA | ||||||||||||
Baseline | 32 (14.5%) | 0.001* | 0.108 | - | 39 (17.7%) | < 0.001* | < 0.001* | a,b,c | 114 (51.8%) | 0.152 | 0.093 | - |
1-year FU | 46 (20.9%) | 71 (32.3%) | 121 (55.0%) | |||||||||
2-year FU | 24 (26.7%) | 34 (37.8%) | 59 (65.6%) | |||||||||
MSA-P | ||||||||||||
Baseline | 22 (20.6%) | 0.026* | 0.232 | - | 27 (25.2%) | < 0.001* | < 0.001* | a | 55 (51.4%) | 0.063 | 0.162 | - |
1-year FU | 29 (27.1%) | 46 (43.0%) | 58 (54.2%) | |||||||||
2-year FU | 17 (37.0%) | 22 (47.8%) | 32 (69.6%) | |||||||||
MSA-C | ||||||||||||
Baseline | 10 (8.8%) | 0.041* | 0.160 | - | 12 (10.6%) | < 0.001* | 0.002* | a | 59 (52.2%) | 0.783 | 0.209 | - |
1-year FU | 17 (15.0%) | 25 (22.1%) | 63 (55.8%) | |||||||||
2-year FU | 7 (15.9%) | 12 (27.3%) | 27 (61.4%) | |||||||||
Male MSA | ||||||||||||
Baseline | 13 (11.4%) | 0.127 | 0.878 | - | 24 (21.1%) | < 0.001* | < 0.001* | a,b,c | 57 (50.0%) | 0.257 | 0.530 | - |
1-year FU | 15 (13.2%) | 42 (36.8%) | 60 (52.6%) | |||||||||
2-year FU | 8 (18.2%) | 22 (50.0%) | 30 (68.2%) | |||||||||
Female MSA | ||||||||||||
Baseline | 19 (17.9%) | 0.003* | 0.022* | a | 15 (14.2%) | < 0.001* | 0.002* | a | 57 (53.8%) | 0.546 | 0.080 | - |
1-year FU | 31 (29.2%) | 29 (27.4%) | 61 (57.5%) | |||||||||
2-year FU | 16 (34.8%) | 12 (26.1%) | 29 (63.0%) |